Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Single-arm, prospective, multi-center, post-approval U.S. registry
This is an all-comers registry that will enroll:
Enrolled patients will fall into one of the following three possible analysis categories:
Patient enrollment in the TOP Registry will continue until 266 eligible DLIDU Primary Analysis Population recipients have been enrolled.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard Donor Lungs Primary Analysis Population | Recipients transplanted with primary analysis population eligible donor lungs preserved on the OCSâ„¢ Lung System. |
| |
| Donor Lungs Initially Unacceptable Primary Analysis Pop. | Recipients transplanted with primary analysis population eligible donor lungs preserved on the OCSâ„¢ Lung System. |
| |
| All Other Enrolled Patients | All OCS Lung transplanted patients that do not meet any of the above analysis populations. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| OCS Lung System | Device | The OCSâ„¢ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCSâ„¢ Lung System accomplishes this by performing 3 key functions:
|
| Measure | Description | Time Frame |
|---|---|---|
| 12-month patient and graft survival post double-lung transplant | Primary Effectiveness Endpoint | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Standard Criteria Donor Lungs - Total ischemic time for OCSâ„¢-preserved lungs | Lung ischemic time | 2 hours |
| Standard Criteria Lungs - Incidence of Primary Graft Dysfunction (PGD) grade 3 within the initial 72 hours post-transplantation (T0, T24, T48, and T72 hours) |
| Measure | Description | Time Frame |
|---|---|---|
| Standard Criteria Lungs - Incidence of PGD3 at T72 hours | Primary Graft Dysfunction | 72 hours |
| Total ischemia and cross-clamp times for 1st and 2nd transplanted lungs | Ischemic and cross-clamp times |
This is an all-comers registry that will enroll all:
Enrolled patients will fall into one of the following three possible analysis categories:
Not provided
Not provided
Not provided
All lung transplant recipients whose donor lungs were preserved on the OCSâ„¢ Lung System
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Joseph's Hospital and Medical Center | Phoenix | Arizona | 85013 | United States | ||
| UCLA |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Primary Graft Dysfunction |
| 0, 24, 48 and 72 hours |
| Donor Lungs Initially Deemed Unacceptable - Incidence of PGD3 at 72 hours post-transplantation | Primary Graft Dysfunction | 72 hours |
| Donor Lungs Initially Deemed Unacceptable - Donor Lung Utilization Rate | Utilization Rate | 1 hour |
| Donor Lungs Initially Deemed Unacceptable - Incidence of PGD3 within the initial 72 hours post-transplantation | Primary Graft Dysfunction | Within 72 hours post-transplantation |
| 2 hours |
| Kaplan-Meier patient survival estimated at Month 1, 6, 12, 24, 36, 48 and 60 | Survival evaluation (K-M) | 1,6,12,24,36,48,60 months |
| Kaplan-Meier BOS-free survival estimated at Month 12, 24, 36, 48 and 60 | BOS free survival (K-M) | 12,24,36,48,60 months |
| Kaplan-Meier Freedom from BOS estimated at Month 12, 24, 36, 48 and 60 | Freedom from BOS (K-M) | 12,24,36,48,60 months |
| Kaplan-Meier graft survival (freedom from re-transplant/graft failure) at Month 12, 24, 36, 48 and 60 | Graft failure | 12,24,36,48,60 months |
| Lung graft-related SAEs through 30 days post-transplant or discharge - Bronchial anastomotic complications; Major pulmonary-related infection | Safety Endpoint | 30 days or hospital discharge (whichever is longer) |
| Survival incidence at 30 days | Safety Endpoint | 30 days |
| Survival incidence at initial transplant surgery hospital discharge, if longer than 30 days. | Safety Endpoint | 30 days or hospital discharge (whichever is longer) |
| Los Angeles |
| California |
| 90095 |
| United States |
| Stanford University | Palo Alto | California | 94304 | United States |
| UCSF | San Francisco | California | 94143 | United States |
| Tampa General Hospital | Tampa | Florida | 33606 | United States |
| Emory | Atlanta | Georgia | 30322 | United States |
| University of Chicago | Chicago | Illinois | 60637 | United States |
| Johns Hopkins | Baltimore | Maryland | 21218 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Henry Ford Health System | Detroit | Michigan | 48202 | United States |
| University of Minnesota | Minneapolis | Minnesota | 55455 | United States |
| Nebraska Medical Center | Omaha | Nebraska | 68198 | United States |
| Duke University | Durham | North Carolina | 27710 | United States |
| Temple University | Philadelphia | Pennsylvania | 19140 | United States |
| Baylor Scott & White Research Institute | Dallas | Texas | 75204 | United States |
| Baylor St. Luke's Medical Center | Houston | Texas | 77030 | United States |
| Houston Methodist | Houston | Texas | 77030 | United States |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | United States |